COVID Vaccines for Young Kids on Hold

9 New ETFs for Investors to Unwrap Created for {EMAIL} | [Web Version]( April 25, 2022 CONNECT WITH KIPLINGER  [LinkedIn]( [Facebook]( [Twitter]( [Instagram ]( [Youtube]( [SIGN UP]( ⋅ [WEBSITE]( [] What's in the Works [] The Food and Drug Administration will likely wait until the summer to authorize a COVID-19 vaccine for children under five, in order to collect more data. The takeup rate for the vaccine for children ages five to 11 has only been 30%, indicating a broad uneasiness among parents to vaccinate their young children. Surveys indicate a similar hesitancy among parents of younger kids. The FDA hopes to authorize both the Pfizer ([PFE]() and Moderna ([MRNA]() vaccines at the same time, making it easier for parents who do want one to find a vaccine. Philadelphia has dropped its indoor mask requirement policy, given the drop in its hospitalization rate. Case numbers are still rising, however. The city had been the only major jurisdiction to reinstate a mask policy in the face of rising infections of the omicron-2 variant, and had been the subject of a lawsuit. Currently, the Biden Administration is appealing a federal judge’s order blocking mask requirements on airlines and other venues under federal jurisdiction. [Learn the most important part of a guarantee.]( For 177 years, New York Life's reputation of strength has garnered it the highest financial ratings.¹ Our goal is to empower financial professionals to give clients more retirement confidence. We offer a range of solutions to meet the full breadth of retirement savers' needs. [READ MORE]( ADVERTISEMENT [] Latest [] Next-generation mRNA vaccines are being developed: CureVac ([CVAC]() and GlaxoSmithKline ([GSK]() announced that their mRNA vaccine targeted at both the beta and delta variants of COVID-19 was effective in animal studies. The vaccine also induced an antibody response to the omicron variant. In just another week or so, [“It’s gonna be May,”]( as the kids would meme, which means it’s time for financial strategists and media alike to ponder that old market yarn – “Sell in May and Go Away.” (Indeed, in a couple days’ time, we will be doing the same.) But today, we look to independent research firm CFRA’s chief investment strategist, Sam Stovall, who provides us with a little breakdown … and advises where investors might find respite from market turmoil. “The ‘sell in May’ adage reminds investors that average May-through-October (M-O) price returns have historically been anemic, not only for large-cap U.S. equities but also for the small-cap, developed international, and emerging market indices, as they recorded average six-month returns of only 1.7% (for the S&P 500), 0.9% (Russell 2000), -1.1% (MSCI-EAFE), and -1.6% (MSCI-EM). In addition, the [November-April] return for each of these four benchmarks outpaced their M-O returns 67% to 78% of the time.” That said, the frequency of gains between May and October ranged anywhere from 44% for the MSCI-EM index to 66% for the S&P 500, implying, as Stovall says, that it has been wiser to “rotate than retreat.” And where might one rotate? “Since 1990, while the overall market was eking out an advance of 2.4% from M-O, the S&P 500 [consumer staples]( and [healthcare]( sectors recorded average price gains of 4.7%. Conversely, as the S&P 500 recorded its strongest six-month return in the N-A period, the cyclical [consumer discretionary](, [industrials](, [materials]( and [technology]( sectors also beat the market as a whole. Indeed, since 1990, while the S&P 500 gained 6.8%, average price gains from equal exposure to these four sectors returned 9.2%.” Free download, [The Kiplinger Letter's Forecast](. No information required from you. [Learn the most important part of a guarantee.]( For 177 years, New York Life's reputation of strength has garnered it the highest financial ratings.¹ Our goal is to empower financial professionals to give clients more retirement confidence. We offer a range of solutions to meet the full breadth of retirement savers' needs. 1. New York Life has received the highest financial strength ratings currently awarded to any U.S. life insurer by Standard & Poor's (AA+); A.M. Best (A++); Moody's (Aaa); and Fitch (AAA). Source: Individual Third-Party Ratings Reports as of 9/30/2021 [READ MORE]( ADVERTISEMENT [] Also on Kiplinger [] - [9 New ETFs for Investors to Unwrap]( - [5 Dumb Crypto Mistakes (And How to Avoid Them)]( - [Choppy Market Impacting Your Retirement Income Plan?]( - [17 Worst Things to Buy at Dollar Stores (Dollar Tree Included)]( - [Sign Up Free for Kiplinger's Retirement E-Newsletter to Plan for and Make the Most of a Rewarding Retirement]( ABOUT KIPLINGER Kiplinger is a trustworthy provider of unbiased, objective financial insight and practical help to millions of business professionals, investors, and individuals seeking to make more profitable decisions with their money. [Kiplinger.com]( attracts 4.5 million unique visits and serves 30 million page views per month. Our [print publications](, also available online and by e-mail delivery, include Kiplinger’s Personal Finance magazine, The Kiplinger Letter, The Kiplinger Tax Letter, Kiplinger’s Retirement Report, and Kiplinger’s Investing for Income. [Sign Up]( | [Print Publications]( | [Unsubscribe]( [Privacy Policy]( | [Cookies Policy]( | [Terms and Conditions]( CONTACT US: [FEEDBACK](concat('mailto:',$brief_feedback_email)) | [ADVERTISE]( Future US LLC © 1100 13th St. NW, Suite 1000, Washington, DC 20005